Enhabit, Inc. (NYSE:EHAB – Get Rating) EVP Ronald Leroy Langham, Jr. bought 10,000 shares of the stock in a transaction dated Thursday, May 18th. The shares were acquired at an average price of $11.99 per share, for a total transaction of $119,900.00. Following the completion of the transaction, the executive vice president now owns 44,328 shares of the company’s stock, valued at approximately $531,492.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Enhabit Stock Performance
Shares of EHAB opened at $12.17 on Tuesday. The company has a quick ratio of 1.59, a current ratio of 1.57 and a debt-to-equity ratio of 0.71. Enhabit, Inc. has a 52-week low of $11.50 and a 52-week high of $25.25. The company has a 50-day simple moving average of $13.02 and a 200-day simple moving average of $13.65. The company has a market capitalization of $609.72 million and a PE ratio of 15.60.
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on EHAB shares. Credit Suisse Group reiterated a “neutral” rating and set a $15.00 target price on shares of Enhabit in a research note on Thursday, February 16th. The Goldman Sachs Group initiated coverage on Enhabit in a report on Thursday, March 16th. They issued a “neutral” rating and a $15.00 target price on the stock. Citigroup decreased their price target on Enhabit from $18.00 to $15.00 in a report on Friday, May 12th. Finally, Stifel Nicolaus boosted their price objective on shares of Enhabit from $17.00 to $18.00 in a research note on Wednesday, February 15th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company. According to MarketBeat, Enhabit has a consensus rating of “Hold” and a consensus target price of $16.13.
Institutional Inflows and Outflows
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
- Get a free copy of the StockNews.com research report on Enhabit (EHAB)
- monday.com Surges on Price and Volume after Blowout Results
- Can Ryanair Stock Fly Above Resistance Levels, What Earnings Show
- All Aboard! The Sell-Side Has Railroads In Reversal
- Is There Value Left in Lyft Stock?
- Everything About ZIM Integrated Screams Undervaluation
Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with MarketBeat.com's FREE daily email newsletter.